To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:8 Issue:2 Number:122 ISSN#:2564-2537
ACE Report #10776
Ace Report Cover Metabolic Disorders

Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy

How to Cite

OrthoEvidence. Periprosthetic bone loss post-total hip arthroplasty mitigated by bisphosphonate therapy. ACE Report. 2019;8(2):122. Available from:

Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A

Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis

J Orthop Surg Res. 2018 Sep 4;13(1):225. doi: 10.1186/s13018-018-0918-7

Contributing Authors:
G Liang J Shi R Huang L Liao D Qin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


12 randomized controlled trials were included in this meta-analysis which sought to evaluate the effect of bisphosphonate therapy in reducing loss of periprosthetic bone mineral density after total hip arthroplasty. In pooled analyses, reduction of periprosthetic bone mineral density was smaller among BP groups compared to control groups within 1 year of surgery, at 2-4 years after surgery, and at...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.